Physician profile
Todd Colonna
NPI 1306826102
$17,298.15
in general payments reported to CMS, 2019-2025
38 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,905 · 2020: $1,301 · 2021: $2,080 · 2022: $2,525 · 2023: $5,132 · 2024: $2,796 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,078 · Consulting Fee: $2,000 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,077.82 |
| Consulting Fee | $2,000.00 |
| Education | $409.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $3,189.16 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $1,844.00 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,587.56 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,111.14 | 2019-2024 | Arazlo, Cabtreo, Jublia |
| Pfizer INC. | $1,071.55 | 2019-2025 | |
| Lilly USA, LLC | $885.47 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $745.70 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $715.84 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $682.74 | 2019-2023 | |
| Ucb, INC. | $589.53 | 2020-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $572.02 | 2019-2025 | Skyrizi |
| Sun Pharmaceutical Industries INC. | $484.27 | 2019-2025 | Ilumya, Winlevi |
| Incyte Corporation | $483.06 | 2021-2025 | Opzelura, Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $478.63 | 2022-2025 | Spevigo, Cyltezo |
| Amgen INC. | $470.64 | 2020-2025 | Otezla, Otezla |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $438.93 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $328.18 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $233.31 | 2019-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $204.64 | 2019-2024 | Dupixent |
| Vyne Pharmaceuticals INC. | $181.86 | 2020-2021 | |
| Organon LLC | $174.20 | 2025 | Vtama |
| Celgene Corporation | $129.73 | 2019 | |
| Dermira, INC. | $105.93 | 2019-2021 | |
| Journey Medical Corporation | $89.50 | 2019-2023 | |
| Epi Health, LLC | $70.67 | 2019-2022 | |
| Encore Dermatology INC. | $69.96 | 2019-2020 | |
| Taro Pharmaceuticals USA, INC. | $55.83 | 2019 | |
| Almirall LLC | $53.89 | 2019-2022 | |
| Lumenis, INC | $47.34 | 2021 | |
| Kyowa Kirin, INC. | $40.49 | 2021-2023 | Poteligeo |
| Botanix Sb INC | $40.05 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $28.08 | 2019-2021 | |
| Promius Pharma LLC | $22.11 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.42 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.40 | 2024 | Ycanth |
| Paratek Pharmaceuticals, INC. | $14.47 | 2022 | |
| Biofrontera INC. | $11.64 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Merck Sharp & Dohme LLC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Colonna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.